ArticleFrontiers in psychiatry2026
Mindfulness-based intervention for patients with generalized anxiety disorder: a randomized controlled trial.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite growing interest in mindfulness-based interventions (MBI) for Generalized Anxiety Disorder (GAD), robust evidence for their adjunctive use alongside first-line pharmacotherapy is scarce. This study aimed to evaluate the efficacy of MBI as adjunct to pharmacotherapy in adults with GAD, assessing multidimensional outcomes. Methods: In this randomized controlled trial, 106 adults diagnosed with DSM-5 GAD and on stable pharmacotherapy were randomly assigned to intervention group or control group (n=53). The intervention group received an 8-week, group-based MBI adapted from Mindfulness-Based Cognitive Therapy in addition to their ongoing pharmacotherapy. The control group received pharmacotherapy plus an active control condition consisting of structured psychoeducation (n=53). The primary outcome was the change in clinician-rated anxiety severity on the Hamilton Anxiety Rating Scale (HAMA). Secondary outcomes included self-reported anxiety (Self-Rating Anxiety Scale, SAS), mindfulness skills (Five Facet Mindfulness Questionnaire, FFMQ), sleep quality (Pittsburgh Sleep Quality Index, PSQI), negative cognitive bias (Negative Cognitive Processing Bias Questionnaire, NCPBQ), and psychosocial functioning (Global Assessment of Functioning-Modified, GAF-M). Linear mixed-effects model was used for analysis. Results: The intervention group demonstrated a significantly greater reduction in HAMA scores post-intervention compared to the control group (18.6 vs. 22.5; Conclusion: An adjunctive, 8-week MBI significantly reduces anxiety and enhances mindfulness, sleep, cognitive function, and psychosocial well-being in medicated GAD patients. These findings support integrating structured MBI into standard care to optimize functional recovery alongside symptom management. Trial registration: The study was registered prior to conducting the research in the Chinese Clinical Trial Registry (https://www.chictr.org.cn) on September 26, 2024 with the trial identification number ChiCTR2400090284.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.